• Supernus Pharmaceuticals completed its merger with Indivior on Nov. 2, 2026, creating a diversified central nervous system drugmaker.
• The combined company will operate as Supernus and begin trading on the Nasdaq Global Market under SUPN on Nov. 3, 2026.
• Supernus holders received 1.5401 Indivior common shares per share, owning approximately 43.5% of the combined company; Indivior holders own approximately 56.5%.
• Indivior stockholders immediately before closing will receive a one-time special cash dividend totaling $1 billion.
• The dividend is funded through a $650 million Citibank term loan facility, with the remainder coming from existing combined-company cash.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020918PRIMZONEFULLFEED9867991) on November 02, 2026, and is solely responsible for the information contained therein.